EIDX News and Press, Eidos Therapeutics Inc. From 08/29/19

In recent years, mountains of institutional capital have flowed into hundreds of biotech start-ups and so many of them have gone public that it's impossible for anyone with a day job to keep track of them all. I'll let you in on a little secret. Those of us paid to know things about the biophar...

In terms of controlling what they can control, I believe Alnylam Pharmaceuticals ( ALNY ) management is doing a good job. While there has certainly been criticism of the high cash burn and the large sums that the company spends on R&D, I believe funding a robust Phase III development pro...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Podcast listener? Subscribe now to receive Wall Street Breakfast by 8:00 a.m. every t...

Forms Special Committee of Independent and Disinterested Directors to Review Proposal Advises Stockholders Take No Action at this Time Eidos Therapeutics, Inc. (Nasdaq:EIDX) (the “Company”) today confirmed that it has received a non-binding proposal dated August 8, 2...

Eidos Therapeutics (NASDAQ: EIDX ) is up 15.4% after hours following a filing that shareholder BridgeBio Pharma (NASDAQ: BBIO ) has made a nonbinding proposal to acquire the rest of the company's shares. More news on: Eidos Therapeutics, Inc., BridgeBio Pharma, Inc., Healthcare stocks ...

Eidos Therapeutics (NASDAQ: EIDX ): Q2 GAAP EPS of -$0.39 in-line. More news on: Eidos Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), today reported its financial results for the second quarter ended June 30, 2019 and provided an update on the company’s recent achievements. “We remain focused on executing our...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Boun...

Bridgebio Pharma (NASDAQ: BBIO ) initiated with Buy rating and $42 (53% upside) price target at Goldman Sachs. Initiated with Buy rating and $38 price target at Jefferies. Initiated with Outperform rating and $49 price target at BMO. Initiated with Outperform rating and $34 price target at S...